Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

Inclusion Criteria:

1. Male and female subjects between the ages of 10-17 years, inclusive, with bipolardisorder (DSM-5 criteria) and 13-17 years, inclusive, in subjects with schizophrenia (DSM-5 criteria).

2. Patients who are judged to be clinically agitated at Screening and Baseline with atotal score of ≥14 on the 5 items comprising the PANSS Excited Component (PEC).

3. Patients who have a score of ≥ 4 on at least 1 of the 5 items on the PEC atBaseline.

4. Participants who agree to use a medically acceptable and effective birth controlmethod

Exclusion Criteria:

1. Patients with agitation caused by acute intoxication, including alcohol or drugs ofabuse (with the exception of THC) during urine screening.

2. Use of benzodiazepines or other hypnotics or oral or short-acting intramuscularantipsychotic drugs in the 4 hours before study treatment.

3. Patients who are judged to be at significant risk of suicide.

4. Patients with serious or unstable medical illnesses.

5. Patients who have received an investigational drug within 30 days prior to thecurrent agitation episode.

6. Patients who are considered by the investigator, for any reason, to be an unsuitablecandidate for receiving the study drug.